Human serum albomin fusion polypeptide
CA 2015687 C · Owner: Novozymes Delta Limited · Inventors: Ballance, David J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of human serum albumin (HSA) or a variant thereof and, as at least part of the C-terminal portion thereof another, polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is one, of various specified entities, including the 585 to 1578 portion of human fibronectin or a variant thereof. The HSA-like portion may have additional Nterminal residues, such as secretion leader sequences (signal sequences). The C-, terminal portion is preferably the 585-1578 portion of human plasma fibronectin. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 27, 1990 and granted August 29, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 27, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 27, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.